病毒学报

[1] Goecke Nicole B, Liang Yuan, Otten Nina D,Hjulsager Charlotte K, Larsen Larse E. Characterization of influenza D virus in danish calves[J/OL]. Viruses,2022, 14(2):423. DOI:10.3390/v14020423.

[2] Javanian Mostafa, Barary Mohammad, Ghebrehewet Sam, Koppolu Veerendra, Vasigala Veneelakrishnarekha, Ebrahimpour Soheil. A brief review of influenza virus infection[J/OL]. J Med Virol,2021, 93(8):4638-4646. DOI:10.1002/jmv.26990.

[3] Walter Mark R. The role of structure in the biology of interferon signaling[J/OL]. Front Immunol, 2020, 11:606489. DOI:10.3389/fimmu.2020.606489.

[4] Kotenko Sergei V, Gallagher Grant, Baurin Vitaliy V,Lewis-Antes Anita, Shen Meiling, Shah Nital K,Langer Jerome A, Sheikh Faruk, Dickensheets Harold,Donnelly Raymond P. Ifn-lambdas mediate antiviral protection through a distinct class ii cytokine receptor complex[J/OL]. Nat Immunol, 2003, 4(1):69-77.DOI:10.1038/ni875.

[5] Jewell Nancy A, Cline Troy, Mertz Sara E, Smirnov Sergey V, Flano Emilio, Schindler Christian, Grieves Jessica L, Durbin Russell K, Kotenko Sergei V, Durbin Joan E. Lambda interferon is the predominant interferon induced by influenza a virus infection in vivo[J/OL]. J Virol, 2010, 84(21):11515-11522. DOI:10.1128/JVI.01703-09.

[6] Klinkhammer Jonas, Schnepf Daniel, Ye Liang,Schwaderlapp Marilena, Gad Hans Henrik, Hartmann Rune, Garcin Dominique, Mahlakoiv Tanel, Staeheli Peter. Ifn-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission[J/OL]. Elife, 2018, 13(7):e33354.DOI:10.7554/eLife.33354.

[7] O'brien Thomas R, Prokunina-Olsson Ludmila,Donnelly Raymond P. Ifn-lambda4:The paradoxical new member of the interferon lambda family[J/OL]. J Interferon Cytokine Res, 2014, 34(11):829-838. DOI:10.1089/jir.2013.0136.

[8] Lazear Helen M, Schoggins John W, Diamond Michael S. Shared and distinct functions of type i and type iii interferons[J/OL]. Immunity, 2019, 50(4):907-923.DOI:10.1016/j.immuni.2019.03.025.

[9] Wack Andreas, Terczynska-Dyla Ewa, Hartmann Rune. Guarding the frontiers:The biology of type iii interferons[J/OL]. Nat Immunol, 2015, 16(8):802-809. DOI:10.1038/ni.3212.

[11]Sabat Robert. Il-10 family of cytokines[J/OL].Cytokine Growth Factor Rev, 2010, 21(5):315-324.DOI:10.1016/j.cytogfr.2010.11.001.

[12]Egli Adrian, Santer Deanna M, O'shea Daire, Tyrrell D Lorne, Houghton Michael. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections[J/OL]. Emerg Microbes Infect, 2014, 3(7):e51. DOI:10.1038/emi.2014.51.

[13]Mesev Emily V, Ledesma Robert A, Ploss Alexander.Decoding type i and iii interferon signalling during viral infection[J/OL]. Nat Microbiol, 2019, 4(6):914-924.DOI:10.1038/s41564-019-0421-x.

[14]Andreakos Evangelos, Salagianni Maria, Galani Ioanna E, Koltsida Ourania. Interferon-lambdas:Front-line guardians of immunity and homeostasis in the respiratory tract[J/OL]. Front Immunol, 2017, 8:1232. DOI:10.3389/fimmu.2017.01232.

[15]Broggi Achille, Tan Yunhao, Granucci Francesca,Zanoni Ivan. Ifn-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function[J/OL]. Nat Immunol, 2017, 18(10):1084-1093. DOI:10.1038/ni.3821.

[16]Hermant Pascale, Michiels Thomas. Interferon-lambda in the context of viral infections:production, response and therapeutic implications[J/OL]. J Innate Immun,2014, 6(5):563-574. DOI:10.1159/000360084.

[17]Cao Yingying, Huang Yaowei, Xu Ke, Liu Yuanhua,Li Xuan, Xu Ye, Zhong Wu, Hao Pei. Differential responses of innate immunity triggered by different subtypes of influenza A viruses in human and avian hosts[J/OL]. BMC Med Genomics, 2017, 10(Suppl 4):70. DOI:10.1186/s12920-017-0304-z.

[18]Van De Sandt Carolien E, Kreijtz Joost H C M,Rimmelzwaan Guus F. Evasion of influenza A viruses from innate and adaptive immune responses[J/OL].Viruses, 2012, 4(9):1438-1476. DOI:10.3390/v4091438.

[19]Chen Xiaoyong, Liu Shasha, Goraya Mohsan Ullah,Maarouf Mohamed, Huang Shile, Chen Ji-Long. Host immune response to influenza A virus infection[J/OL].Front Immunol, 2018, 9:320. DOI:10.3389/fimmu.2018.00320.

[20]Hagau Natalia, Slavcovici Adriana, Gonganau Daniel N, Oltean Simona, Dirzu Dan S, Brezoszki Erika S,Maxim Mihaela, Ciuce Constantin, Mlesnite Monica,Gavrus Rodica L, Laslo Carmen, Hagau Radu,Petrescu Magda, Studnicska Daniela M. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection[J/OL]. Crit Care, 2010, 14(6):R203. DOI:10.1186/cc9324.

[21]Brogaard Louise, Larsen Lars E, Heegaard Peter M H,Anthon Christian, Gorodkin Jan, Durrwald Ralf,Skovgaard Kerstin. IFN-lambda and micrornas are important modulators of the pulmonary innate immune response against influenza a(H1N2)infection in pigs[J/OL]. PLoS One, 2018, 13(4):e0194765. DOI:10.1371/journal.pone.0194765.

[22]Xie Ping. TRAF molecules in cell signaling and in human diseases[J/OL]. J Mol Signal, 2013, 8(1):7.DOI:10.1186/1750-2187-8-7.

[23]Jacobs Jana L, Coyne Carolyn B. Mechanisms of mavs regulation at the mitochondrial membrane[J/OL]. J Mol Biol, 2013, 425(24):5009-5019. DOI:10.1016/j.jmb.2013.10.007.

[24]Coates Bria M, Staricha Kelly L, Wiese Kristin M,Ridge Karen M. Influenza A virus infection, innate immunity, and childhood[J/OL]. JAMA Pediatr,2015, 169(10):956-963. DOI:10.1001/jamapediatrics.2015.1387.

[25]Kato Hiroki, Takeuchi Osamu, Sato Shintaro,Yoneyama Mitsutoshi, Yamamoto Masahiro, Matsui Kosuke, Uematsu Satoshi, Jung Andreas, Kawai Taro,Ishii Ken J, Yamaguchi Osamu, Otsu Kinya, Tsujimura Tohru, Koh Chang-Sung, Reis E Sousa Caetano,Matsuura Yoshiharu, Fujita Takashi, Akira Shizuo.Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses[J/OL]. Nature, 2006, 441(7089):101-105. DOI:10.1038/nature04734.

[26]Onoguchi Kazuhide, Yoneyama Mitsutoshi, Takemura Azumi, Akira Shizuo, Taniguchi Tadatsugu, Namiki Hideo, Fujita Takashi. Viral infections activate types i and iii interferon genes through a common mechanism[J/OL]. J Biol Chem, 2007, 282(10):7576-7581.DOI:10.1074/jbc.M608618200.

[27]Mikkelsen Susie S, Jensen Soren B, Chiliveru Srikanth, Melchjorsen Jesper, Julkunen Ilkka, Gaestel Matthias, Arthur J Simon C, Flavell Richard A, Ghosh Sankar, Paludan Soren R. Rig-i-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells:Dependence on TRAF2and TAK1[J/OL]. J Biol Chem, 2009, 284(16):10774-10782. DOI:10.1074/jbc.M807272200.

[28]Durbin Russell K, Kotenko Sergei V, Durbin Joan E.Interferon induction and function at the mucosal surface[J/OL]. Immunol Rev, 2013, 255(1):25-39. DOI:10.1111/imr.12101.

[29]Lazear Helen M, Nice Timothy J, Diamond Michael S.Interferon-lambda:Immune functions at barrier surfaces and beyond[J/OL]. Immunity, 2015, 43(1):15-28.DOI:10.1016/j.immuni.2015.07.001.

[30]Hao Nannan, Zhou Zihao, Zhang Feifei, Li Yong, Hu Rui, Zou Junjie, Zheng Rui, Wang Lei, Xu Lingxiao,Tan Wenfeng, Li Chunjian, Wang Fang. Interleukin-29accelerates vascular calcification via JAK2/STAT3/BMP2 signaling[J/OL]. J Am Heart Assoc, 2023, 12(1):e027222. DOI:10.1161/JAHA.122.027222.

[31]Zhou Zhangle, Hamming Ole J, Ank Nina, Paludan Soren R, Nielsen Anders L, Hartmann Rune. Type iii interferon(IFN)induces a type i IFN-like response in a restricted subset of cells through signaling pathways involving both the JAK-STAT pathway and the mitogenactivated protein kinases[J/OL]. J Virol, 2007, 81(14):7749-7758. DOI:10.1128/JVI.02438-06.

[32]Kroczynska Barbara, Joshi Sonali, Eklund Elizabeth A,Verma Amit, Kotenko Sergei V, Fish Eleanor N,Platanias Leonidas C. Regulatory effects of ribosomal s6kinase 1(RSK1)in IFNlambda signaling[J/OL]. J Biol Chem, 2011, 286(2):1147-1156. DOI:10.1074/jbc.M110.183566.

[33]Plotnikova Marina, Lozhkov Alexey, RomanovskayaRomanko Ekaterina, Baranovskaya Irina, Sergeeva Mariia, KааKonstantin, Klotchenko Sergey, Vasin Andrey. IFN-λ1 displays various levels of antiviral activity in vitro in a select panel of RNA viruses[J/OL]. Viruses, 2021, 13(8):1602. DOI:10.3390/v13081602.

[34]Svetlikova Darina, Kabat Peter, Ohradanova Anna,Pastorek Jaromir, Betakova Tatiana. Influenza a virus replication is inhibited in IFN-lambda2 and IFN-lambda3transfected or stimulated cells[J/OL]. Antiviral Res,2010, 88(3):329-333. DOI:10.1016/j.antiviral.2010.10.005.

[35]Sun Yeping, Jiang Jingwen, Tien Po, Liu Wenjun, Li Jing. IFN-λ：A new spotlight in innate immunity against influenza virus infection[J/OL]. Protein Cell, 2018, 9(10):832-837. DOI:10.1007/s13238-017-0503-6.

[36]Lopusna K, Rezuchova I, Betakova T, Skovranova L,Tomaskova J, Lukacikova L, Kabat P. Interferons lambda, new cytokines with antiviral activity[J/OL].Acta Virol, 2013, 57(2):171-179. DOI:10.4149/av_2013_02_171.

[37]Xiao Han, Killip Marian J, Staeheli Peter, Randall Richard E, Jackson David. The human interferoninduced MXA protein inhibits early stages of influenza A virus infection by retaining the incoming viral genome in the cytoplasm[J/OL]. J Virol, 2013, 87(23):13053-13058. DOI:10.1128/JVI.02220-13.

[38]Ciancanelli Michael J, Abel Laurent, Zhang ShenYing, Casanova Jean-Laurent. Host genetics of severe influenza:From mouse MX1 to human IRF7[J/OL].Curr Opin Immunol, 2016, 38:109-120. DOI:10.1016/j.coi.2015.12.002.

[39]Meyerson Nicholas R, Zhou Ligang, Guo Yusong R,Zhao Chen, Tao Yizhi J, Krug Robert M, Sawyer Sara L. Nuclear TRIM25 specifically targets influenza virus ribonucleoproteins to block the onset of RNA chain elongation[J/OL]. Cell Host Microbe, 2017, 22(5):627-638 e627. DOI:10.1016/j.chom.2017.10.003.

[40]Pagani Isabel, Poli Guido, Vicenzi Elisa. TRIM22. A multitasking antiviral factor[J/OL]. Cells, 2021, 10(8):1864. DOI:10.3390/cells10081864.

[41]Fu Bishi, Wang Lingyan, Ding Hao, Schwamborn Jens C, Li Shitao, Dorf Martin E. TRIM32 senses and restricts influenza A virus by ubiquitination of PB1polymerase[J/OL]. PLoS Pathog, 2015, 11(6):e1004960. DOI:10.1371/journal.ppat.1004960.

[42]Morales David J, Monte Kristen, Sun Lulu, Struckhoff Jessica J, Agapov Eugene, Holtzman Michael J,Stappenbeck Thaddeus S, Lenschow Deborah J. Novel mode of ISG15-mediated protection against influenza A virus and Sendai virus in mice[J/OL]. J Virol, 2015,89(1):337-349. DOI:10.1128/JVI.02110-14.

[43]Dauber Bianca, Martinez-Sobrido Luis, Schneider Jana,Hai Rong, Waibler Zoe, Kalinke Ulrich, Garcia-Sastre Adolfo, Wolff Thorsten. Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR[J/OL]. PLoS Pathog, 2009, 5(6):e1000473. DOI:10.1371/journal.ppat.1000473.

[44]Abbas Yazan M, Pichlmair Andreas, Gorna Maria W,Superti-Furga Giulio, Nagar Bhushan. Structural basis for viral 5'-ppp-RNA recognition by human IFIT proteins[J/OL]. Nature, 2013, 494(7435):60-64.DOI:10.1038/nature11783.

[45]Pizzolla Angela, Wakim Linda M. Memory T cell dynamics in the lung during influenza virus infection[J/OL]. J Immunol, 2019, 202(2):374-381. DOI:10.4049/jimmunol.1800979.

[46]Hemann Emily A, Green Richard, Turnbull J Bryan,Langlois Ryan A, Savan Ram, Gale Michael. Interferonlambda modulates dendritic cells to facilitate T cell immunity during infection with influenza a virus[J/OL].Nat Immunol, 2019, 20(8):1035-1045. DOI:10.1038/s41590-019-0408-z.

[47]Krammer Florian, Palese Peter, Steel John. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin[J/OL]. Curr Top Microbiol Immunol,2015, 386:301-321. DOI:10.1007/82_2014_408.

[48]Nachbagauer Raffael, Palese Peter. Is a universal influenza virus vaccine possible?[J/OL]. Annu Rev Med, 2020, 71(1):315-327. DOI:10.1146/annurevmed-120617-041310.

[49]Amarelle Luciano, Lecuona Emilia, Sznajder Jacob I.Anti-influenza treatment:Drugs currently used and under development[J/OL]. Arch Bronconeumol,2017, 53(1):19-26. DOI:10.1016/j.arbres.2016.07.004.

[50]Lozhkov Alexey A, Klotchenko Sergey A, Ramsay Edward S, Moshkoff Herman D, Moshkoff Dmitry A,Vasin Andrey V, Salvato Maria S. The key roles of interferon lambda in human molecular defense against respiratory viral infections[J/OL]. Pathogens, 2020, 9(12):989. DOI:10.3390/pathogens9120989.

[51]Davidson Sophia, Mccabe Teresa M, Crotta Stefania,Gad Hans Henrik, Hessel Edith M, Beinke Soren,Hartmann Rune, Wack Andreas. Ifnlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment[J/OL]. EMBO Mol Med, 2016, 8(9):1099-1112. DOI:10.15252/emmm.201606413.

[52]Mordstein Markus, Neugebauer Eva, Ditt Vanessa,Jessen Birthe, Rieger Toni, Falcone Valeria, Sorgeloos Frederic, Ehl Stephan, Mayer Daniel, Kochs Georg,Schwemmle Martin, Gunther Stephan, Drosten Christian, Michiels Thomas, Staeheli Peter. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections[J/OL]. J Virol, 2010, 84(11):5670-5677. DOI:10.1128/JVI.00272-10.

[53]Galani Ioanna E, Triantafyllia Vasiliki, Eleminiadou Evridiki-Evangelia, Koltsida Ourania, Stavropoulos Athanasios, Manioudaki Maria, Thanos Dimitris,Doyle Sean E, Kotenko Sergei V, Thanopoulou Kalliopi, Andreakos Evangelos. Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness[J/OL]. Immunity, 2017, 46(5):875-890.e876. DOI:10.1016/j.immuni.2017.04.025.

[54]Martinez-Espinoza Ivan, Guerrero-Plata Antonieta.Current landscape of ifn-lambda:Induction, inhibition,and potential clinical applications to treat respiratory viral infections[J/OL]. Immunohorizons, 2023, 7(4):265-272. DOI:10.4049/immunohorizons.2200010.

[55]Andreakos Evangelos, Tsiodras Sotirios. Covid-19:Lambda interferon against viral load and hyperinflammation[J/OL]. EMBO Mol Med, 2020, 12(6):e12465. DOI:10.15252/emmm.202012465.

[56]Reis Gilmar, Moreira Silva Eduardo a S, Medeiros Silva Daniela C, Thabane Lehana, Campos Vitoria H S, Ferreira Thiago S, Santos Castilho V Q, Nogueira Ana M R, Almeida Ana P F G, Savassi Leonardo C M, Figueiredo-Neto Adhemar D, Dias Ana C F, Freire Junior Adelino M, Bitaraes Carina, Milagres Aline C,Callegari Eduardo D, Simplicio Maria I C, Ribeiro Luciene B, Oliveira Rosemary, Harari Ofir, Wilson Lindsay A, Forrest Jamie I, Ruton Hinda, Sprague Sheila, Mckay Paula, Guo Christina M, LimbrickOldfield Eve H, Kanters Steve, Guyatt Gordon H,Rayner Craig R, Kandel Christopher, Biondi Mia J,Kozak Robert, Hansen Bettina, Zahoor M Atif, Arora Paul, Hislop Colin, Choong Ingrid, Feld Jordan J,Mills Edward J, Glenn Jeffrey S, Investigators Together. Early treatment with pegylated interferon lambda for COVID-19[J/OL]. N Engl J Med, 2023,388(6):518-528. DOI:10.1056/NEJMoa2209760.

[57]Phillips Sandra, Mistry Sameer, Riva Antonio,Cooksley Helen, Hadzhiolova-Lebeau Tanya, Plavova Slava, Katzarov Krum, Simonova Marieta, Zeuzem Stephan, Woffendin Clive, Chen Pei-Jer, Peng ChengYuan, Chang Ting-Tsung, Lueth Stefan, De Knegt Robert, Choi Moon-Seok, Wedemeyer Heiner, Dao Michael, Kim Chang-Wook, Chu Heng-Chen, WindRotolo Megan, Williams Roger, Cooney Elizabeth,Chokshi Shilpa. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients[J/OL]. Front Immunol, 2017, 8:621.DOI:10.3389/fimmu.2017.00621.

[58]Broggi Achille, Ghosh Sreya, Sposito Benedetta,Spreafico Roberto, Balzarini Fabio, Lo Cascio Antonino, Clementi Nicola, De Santis Maria, Mancini Nicasio, Granucci Francesca, Zanoni Ivan. Type iii interferons disrupt the lung epithelial barrier upon viral recognition[J/OL]. Science, 2020, 369(6504):706-712. DOI:10.1126/science.abc3545.

[59]Planet Paul J., Parker Dane, Cohen Taylor S., Smith Hannah, Leon Justinne D., Ryan Chanelle, Hammer Tobin J., Fierer Noah, Chen Emily I., Prince Alice S.,Schneewind Olaf. Lambda interferon restructures the nasal microbiome and increases susceptibility to staphylococcus aureus superinfection[J/OL]. mBio,2016, 7(1):e01939-01915. DOI:10.1128/mBio.01939-15.

[60]Goel Rishi R, Wang Xinghao, O'neil Liam J, Nakabo Shuichiro, Hasneen Kowser, Gupta Sarthak, Wigerblad Gustaf, Blanco Luz P, Kopp Jeffrey B, Morasso Maria I, Kotenko Sergei V, Yu Zu-Xi, Carmona-Rivera Carmelo, Kaplan Mariana J. Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus[J/OL]. Proc Natl Acad Sci U S A,2020, 117(10):5409-5419. DOI:10.1073/pnas.1916897117.